What can neutralizing antibodies tell us about the quality of immunity in COVID-19 convalescents and vaccinees?

References

• Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Hu Y, Tao ZW, Tian JH, Pei YY, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265–11. doi:10.1038/s41586-020-2008-3.
   PubMed Web of Science ®Google Scholar
• Medicines and Healthcare products Regulatory Agency. Regulatory approval of Pfizer/BioNTech vaccine for COVID-19. 2020.
   Google Scholar
• Knezevic I, Mattiuzzo G, Page M, Minor P, Griffiths E, Nuebling M, Moorthy V. WHO International standard for evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific community. Lancet Microbe. 2022;3(3):e235–40. doi:10.1016/S2666-5247(21)00266-4.
   PubMedGoogle Scholar
• Bernasconi V. Use WHO antibody standards for emergency vaccine testing. Nature. 2023;613(7943):243. doi:10.1038/d41586-023-00007-2.
   PubMed Web of Science ®Google Scholar
• Earle KA, Ambrosino DM, Fiore-Gartland A, Goldblatt D, Gilbert PB, Siber GR, Dull P, Plotkin SA. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine. 2021;39(32):4423–8. doi:10.1016/j.vaccine.2021.05.063.
   PubMed Web of Science ®Google Scholar
• Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med [Internet]. 2021;27(7):1205–11. doi:10.1038/s41591-021-01377-8.
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Fiore-Gartland A, Johnson M, Hunt A, Bengt C, Zavadska D, Snipe HD, Brown JS, Workman L, Zar HJ, et al. Towards a population-based threshold of protection for COVID-19 vaccines. Vaccine. 2022;40(2):306–15. doi:10.1016/j.vaccine.2021.12.006.
   PubMed Web of Science ®Google Scholar
• Van Gils MJ, Lavell A, van der Straten K, Appelman B, Bontjer I, Poniman M, Burger JA, Oomen M, Bouhuijs JH, van Vught LA, et al. Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: a prospective cohort study. PLoS Med [Internet]. 2022;19(5):1–21. doi:10.1371/journal.pmed.1003991.
   Web of Science ®Google Scholar
• Ravlić S, Hećimović A, Kurtović T, Ivančić Jelečki J, Forčić D, Slović A, Kurolt IC, Mačak Šafranko Ž, Mušlin T, Rnjak D, et al. Is better standardization of therapeutic antibody quality in emerging Diseases epidemics possible? Front Immunol. 2022;13:1–12. doi:10.3389/fimmu.2022.816159.
   Web of Science ®Google Scholar
• Kristiansen PA, Page M, Bernasconi V, Mattiuzzo G, Dull P, Makar K, Plotkin S, Knezevic I. WHO International standard for anti-SARS-CoV-2 immunoglobulin. Lancet. 2021;397(10282):1347–8. doi:10.1016/S0140-6736(21)00527-4.
   PubMed Web of Science ®Google Scholar
• Brgles M, Kurtović T, Lang Balija M, Hećimović A, Mušlin T, Halassy B. Impact of complement and difference of cell-based assay and ELISA in determination of neutralization capacity against mumps and measles virus. J Immunol Methods [Internet]. 2021;490:112957. doi:10.1016/j.jim.2021.112957.
   PubMed Web of Science ®Google Scholar
• Karbiener M, Farcet MR, Zollner A, Masuda T, Mori M, Moschen AR, Kreil TR. Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines. NPJ Vaccines. 2022;7(1):2–4. doi:10.1038/s41541-022-00455-3.
   PubMed Web of Science ®Google Scholar
• Wohlgemuth N, Whitt K, Cherry S, Kirkpatrick Roubidoux E, Lin C-Y, Allison KJ, Gowen A, Freiden P, Allen EK, Gaur AH, et al. An assessment of serological assays for SARS-CoV-2 as surrogates for authentic virus neutralization. Microbiol Spectr. 2021;9(2). doi:10.1128/Spectrum.01059-21.
   PubMed Web of Science ®Google Scholar
• Lippi G, Adeli K, Plebani M. Commercial immunoassays for detection of anti-SARS-CoV-2 spike and RBD antibodies: urgent call for validation against new and highly mutated variants. Clin Chem Lab Med. 2022;60(3):338–42. doi:10.1515/cclm-2021-1287.
   PubMed Web of Science ®Google Scholar
• Saadat S, Rikhtegaran Tehrani Z, Logue J, Newman M, Frieman MB, Harris AD, Sajadi MM. Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2. JAMA. 2021;325:1467–8. doi:10.1001/jama.2021.3341.
   PubMed Web of Science ®Google Scholar
• Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF, Bermudez-Gonzalez MC, Bielak DA, Carreño JM, Chernet RL. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med. 2021;384(14):1372–4. doi:10.1056/NEJMc2101667.
   PubMed Web of Science ®Google Scholar
• Anichini G, Terrosi C, Gandolfo C, Savellini GG, Fabrizi S, Miceli GB, Cusi MG. SARS-CoV-2 antibody response in persons with past natural infection. N Engl J Med. 2023;385:90–2. doi:10.1056/NEJMc2103825.
   Web of Science ®Google Scholar
• Manisty C, Otter AD, Treibel TA, McKnight Á, Altmann DM, Brooks T, Noursadeghi M, Boyton RJ, Semper A, Moon JC. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet. 2021;397:1057–8. doi:10.1016/S0140-6736(21)00501-8.
   PubMed Web of Science ®Google Scholar
• Vicenti I, Gatti F, Scaggiante R, Boccuto A, Zago D, Basso M, Dragoni F, Parisi SG, Zazzi M. The second dose of the BNT162b2 mRNA vaccine does not boost SARS-CoV-2 neutralizing antibody response in previously infected subjects. Infection [Internet]. 2022;50(2):541–3. doi:10.1007/s15010-021-01680-z.
   PubMed Web of Science ®Google Scholar
• Claro F, Silva D, Rodriguez M, Rangel HR, De JH Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and mandarin on the novel coronavirus COVID- 19. The COVID-19 resource centre is hosted on Elsevier Connect, the company ’ s public news and information. 2020;
   Google Scholar
• Jahrsdörfer B, Fabricius D, Scholz J, Ludwig C, Grempels A, Lotfi R, Körper S, Adler G, Schrezenmeier H. BNT162b2 vaccination elicits strong serological immune responses against SARS-CoV-2 including variants of concern in elderly convalescents. Front Immunol. 2021;12:1–13. doi:10.3389/fimmu.2021.743422.
   Web of Science ®Google Scholar
• Wei J, Pouwels KB, Stoesser N, Matthews PC, Diamond I, Studley R, Rourke E, Cook D, Bell JI, Newton JN, et al. Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. Nat Med. 2022;28(5):1072–82. doi:10.1038/s41591-022-01721-6.
   PubMed Web of Science ®Google Scholar
• Agrawal P, Nawadkar R, Ojha H, Kumar J, Sahu A. Complement evasion strategies of viruses: an overview. Front Microbiol. 2017;8:1–19. doi:10.3389/fmicb.2017.01117.
   PubMed Web of Science ®Google Scholar
• Pastorino B, Touret F, Gilles M, De Lamballerie X. Heat inactivation of different types of SARS-CoV-2 samples: what protocols for biosafety, molecular detection and serological diagnostics? Viruses. 2020;12:6–13. doi:10.3390/v12070735.
   Web of Science ®Google Scholar
• Jarlhelt I, Nielsen SK, Jahn CXH, Hansen CB, Pérez-Alós L, Rosbjerg A, Bayarri-Olmos R, Skjoedt MO, Garred P. SARS-CoV-2 antibodies mediate complement and cellular driven inflammation. Front Immunol. 2021;12:1–11. doi:10.3389/fimmu.2021.767981.
   Web of Science ®Google Scholar
• Lamerton RE, Marcial-Juarez E, Faustini SE, Perez-Toledo M, Goodall M, Jossi SE, Newby ML, Chapple I, Dietrich T, Veenith T, et al. SARS-CoV-2 Spike- and nucleoprotein-specific antibodies induced after vaccination or infection promote classical complement activation. Front Immunol. 2022;13:1–13. doi:10.3389/fimmu.2022.838780.
   Web of Science ®Google Scholar
• Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement system part I - molecular mechanisms of activation and regulation. Front Immunol. 2015;6:1–30. doi:10.3389/fimmu.2015.00262.
   PubMed Web of Science ®Google Scholar
• Jegerlehner A, Storni T, Lipowsky G, Schmid M, Pumpens P, Bachmann MF. Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. Eur J Immunol. 2002;32(11):3305–14. doi:10.1002/1521-4141(200211)32:11<3305:AID-IMMU3305>3.0.CO;2-J.
   PubMed Web of Science ®Google Scholar
• Kurtović T, Ravlić S, Štimac A, Mateljak Lukačević S, Hećimović A, Kazazić S, Halassy B. Efficient and sustainable platform for preparation of a high-quality immunoglobulin G as an urgent treatment option during emerging virus outbreaks. Front Immunol. 2022;13:1–11. doi:10.3389/fimmu.2022.889736.
   Web of Science ®Google Scholar
• Andreano E, Paciello I, Piccini G, Manganaro N, Pileri P, Hyseni I, Leonardi M, Pantano E, Abbiento V, Benincasa L, et al. Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants. Nature. 2021;600(7889):530–5. doi:10.1038/s41586-021-04117-7.
   PubMed Web of Science ®Google Scholar
• Stein C, Nassereldine H, Sorensen RJD, Amlag JO, Bisignano C, Byrne S, Castro E, Coberly K, Collins JK, Dalos J, et al. Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. Lancet. 2023;401(10379):833–42. doi:10.1016/S0140-6736(22)02465-5.
   PubMed Web of Science ®Google Scholar